Market Overview

OncoSec to Present at H.C. Wainwright 20th Annual Global Investment Conference

Share:

OncoSec to Present at H.C. Wainwright 20th Annual Global Investment Conference

PR Newswire

SAN DIEGO and PENNINGTON, N.J., Aug. 31, 2018 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that Daniel J. O'Connor, President and Chief Executive Officer of OncoSec, will present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6, 2018 at 11:15 a.m. ET in New York City.

A live audio webcast of the presentation will be available on the Investors section of OncoSec's website at ir.oncosec.com, where it will be archived for approximately 30 days.

About OncoSec Immunotherapies
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.  OncoSec's lead immunotherapy platform – TAVO (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders.  Results from recently completed clinical studies of TAVO have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach.  In addition to TAVO, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its ImmunoPulse® platform. For more information, please visit www.oncosec.com.

CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com

Media Relations:
David Schemelia / Jason Rando
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
dschemelia@tiberend.com
jrando@tiberend.com

OncoSec Medical Incorporated logo (PRNewsfoto/OncoSec Medical Incorporated)

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/oncosec-to-present-at-hc-wainwright-20th-annual-global-investment-conference-300705316.html

SOURCE OncoSec Medical Incorporated

View Comments and Join the Discussion!